Atherogenic lipoproteins for the statin residual cardiovascular disease risk

HIGHLIGHTS

  • who: Hidekatsu Yanai and collaborators from the Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, Kohnodai, Chiba, Japan have published the research work: Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk, in the Journal: (JOURNAL)
  • what: The study shows that elevated triglyceride (TG) levels reduced high-density lipoprotein cholesterol (HDL-C) and the existence of obesity/insulin resistance and diabetes may be important metabolic factors that determine CVD risk. One of the studies showed that, among eight RCTs that investigated the effect of statins vs. a placebo . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?